To further identify the potential biological mechanisms of SGLT2 inhibitors on prostate cancer, we applied MELODI Presto27 to identify potential mediators that can link SGLT2 inhibitors with prostate cancer. Here, SLC5A2 is linked to prostate carcinoma.